Almac Diagnostics discusses new biomarker service

By Gareth Macdonald

- Last updated on GMT

Related tags: Pharmacology

Almac Diagnostics discusses new biomarker service
Almac says an effective biomarker strategy boosts a drug candidates’ chance of success and can ultimately add value to a developer’s business by opening door to diagnostics.

Earlier this month Almac’s diagnostics arm launched a new biomarker development service which, as VP of business development Michael Sloan told Outsourcing-pharma, is intended to cater for growing biopharmaceutical manufacturing sector demand.

Sloan explained that demand for pharmacodynamic biomarkers, as well as those for clinical trial enrichment, is increasing day by day as everyone from Big Pharma to biotech recognises their value in the drug development process.

He also suggested that, increasingly, such companies are adopting broader strategies involving commercial development of biomarkers for in clinic diagnostics purposes which, while a new market, is one in which he sees considerable growth potential.

Related news

Show more

Related products

show more

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us

Products

View more

Webinars